GLP-1s: More Than a Tool for Weight Loss

  • White Paper
  • Obesity care and GLP-1s

Summary

As more data becomes available about the benefits of GLP-1s, it is clear these medications are more than a tool for weight loss and could play a significant role in the prevention and treatment of chronic disease. It is now more important than ever for employers and health plans to reimagine their strategies around GLP-1 coverage to ensure they are prepared to address the changing healthcare landscape and the influence GLP-1s will have on population health.

Download our white paper to discover:

  • The latest research on the health benefits of GLP-1s
  • Strategies to balance access with cost effectiveness
  • Why behavior change support is essential to GLP-1 success
  • What smarter healthcare spending could look like

Download the White Paper

"*" indicates required fields

* Required Fields
This field is for validation purposes and should be left unchanged.

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • Obesity care and GLP-1s
  • March 28
  • 1 min read

The GLP-1 Shortage: What It Means and Why It Still Matters

Over the last few years, GLP-1 and GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound gained widespread traction for tackling obesity and supporting long-term weight loss efforts*. They decrease appetite, regulate blood sugar, and deliver consistent weight loss results for individuals struggling to manage their metabolic health. However, with the surge in demand comes […]

By Noom Team
  • Blog
  • Obesity care and GLP-1s
  • March 28
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
  • Blog
  • Obesity care and GLP-1s
  • March 28
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO